Human growth hormone (hGH) or somatotropin is a peptide hormone responsible for cell reproduction, growth stimulation, and cell regeneration in humans. In human growth hormone (GH) deficiency is caused when the pituitary gland is unable to synthesize enough concentration of hGH. This deficiency is treated by subcutaneously administering recombinant hGH. Various genetic disorders, including Turner syndrome and Prader–Willi syndrome, may cause growth hormone deficiency in humans, leading to shorter-than-average height and delayed puberty.
According to data published by the American Academy of Pediatrics, in the U.S., growth hormone deficiency affects less than one in 3,000 to one in 10,000 children. hGH is currently being abused by bodybuilders and athletes as an anti-aging treatment and as a performance-enhancing anabolic drug. However, according to the USFDA, hGH is a controlled substance that has not been authorized for anti-aging or performance-enhancing purposes.
COVID-19 Impact analysis
Following the COVID-19 outbreak, the emphasis has shifted toward the enhanced production of effective and affordable drugs, with the pandemic shining a light on healthcare inequities. For the accelerated drug development rate, the demand for real-world evidence has increased considerably, with major companies now opting for remote monitoring as well as source document verification (SDV), ensuring that patients can benefit despite the COVID-19 pandemic. While COVID-19 gets healthcare’s attention, growth hormone deficiency continues to be the focus areas in many countries. Therefore, studies are in progress to know the importance of growth hormone drugs and foster their application scope. In the post-pandemic era, the demand for the pediatric growth hormone market has also been favorable.
Top Impacting Factors
- The market growth is attributed to increase in growth hormone deficiency disorders and rise in growth hormone usage to control aging.
- In addition, rise in awareness of the treatment procedure and increase in neuropsychiatric cases propel the human growth hormone market.
- The introduction of novel therapies as well as robust pipeline and surge in R&D investments augment the market growth.
- However, high cost of the treatment and fluctuations in drug productivity in pharmaceutical companies restraint the market growth.
- Side effects such as fluid retention, joint pain, and muscle pain related to synthetic growth hormones are the key deterrent factors for market growth.
- The surge in FDA approvals is also providing opportunities to the key players to develop novel drugs that have fewer side effects.
Market Trends
New product launches to flourish the market
In September 2018, Novo Nordisk presented Phase II clinical trial data of its investigational GH therapy, Somapacitan, indicated for the treatment of pediatric growth hormone deficiency.
In May 2019, Ascendis Pharma A/S published results from the Phase III clinical trial of its TransCon hGH, indicated for pediatric growth hormone deficiency.
In November 2020, GenScience Pharmaceuticals entered an exclusive agreement with Foresee Pharmaceuticals for commercializing the latter’s FP-001 program, Leuprolide Mesylate Injectable Suspension—subcutaneous, ready-to-use 3-month and 6-month depot formulations or Camcevi. This agreement will be solely focusing on the Chinese market.
November 2020, Aeterna teamed up with Novo Nordisk with the aim to boost the application scope of macimorelin that helps diagnose growth hormone deficiency, which is childhood onset. The company believes that this area is considerably untapped, and therefore needs to explore the unmet needs. Aeterna is currently in the early stage of clinical safety as well as efficacy study, which focuses on analyzing Macimorelin for detection of CGHD.
Surge in GH Deficiency Cases to be a Key Growth Booster
Growth hormone deficiency has become a huge problem for the healthcare industry, and the most common reason for the same is considered to be a brain injury. This condition is marked with a host of symptoms, such as reduced energy levels, lower muscle strength, altered body composition, osteoporosis, insulin resistance, and lipid abnormalities that include high LDL cholesterol. Therefore, the growth hormone market share is expected to be bolstered by the rising GH deficiency disorders worldwide.
Key Benefits of the Report
- This study presents the analytical depiction of the growth hormone deficiency along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions Answered in the Growth Hormone Deficiency Report
- Which are the leading players active in the growth hormone deficiency market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is "growth hormone deficiency "?
- What is "growth hormone deficiency” market prediction in the future?
- Who are the leading global players in the "growth hormone deficiency” market?
- What are the current trends and predicted trends?
- What are the key benefits of the "growth hormone deficiency” market report?
Growth Hormone Deficiency Market Report Highlights
| Aspects | Details |
 By Brand |
|
 By Application |
|
 By End User |
|
 By Region |
|
 Key Market Players | Ferring B.V., Eli Lilly and Company, Merck KGaA, Ipsen, Roche, Pfizer, Inc, Ferring Pharmaceuticals, Teva Pharmaceutical Industries, Ltd, Novo Nordisk A/S, Novartis AG |
Loading Table Of Content...
